PhaseBio Pharmaceuticals, Inc. (PHAS) financial statements (2020 and earlier)

Company profile

Business Address 1 GREAT VALLEY PARKWAY
MALVERN, PA 19355
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7461
Cash and cash equivalents7461
Restricted cash and investments 0
Receivables10
Other undisclosed current assets41
Total current assets:7963
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment20
Other noncurrent assets00
Total noncurrent assets:40
TOTAL ASSETS:8263
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities65
Accounts payable32
Accrued liabilities33
Debt2 
Total current liabilities:85
Noncurrent Liabilities
Long-term debt and lease obligation148
Long-term debt, excluding current maturities128
Operating lease, liability2
Liabilities, other than long-term debt00
Deferred rent credit 0
Other liabilities0 
Total noncurrent liabilities:148
Total liabilities:2312
Stockholders' equity
Stockholders' equity attributable to parent6051
Common stock00
Treasury stock, value(0)(0)
Additional paid in capital222174
Accumulated deficit(162)(123)
Total stockholders' equity:6051
TOTAL LIABILITIES AND EQUITY:8263

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:21
Operating expenses(42)(20)
Operating loss:(40)(20)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
0(4)
Interest and debt expense(1)(4)
Loss before gain (loss) on sale of properties:(40)(28)
Other undisclosed net income14
Net loss available to common stockholders, diluted:(39)(24)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(39)(24)
Comprehensive loss, net of tax, attributable to parent:(39)(24)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: